Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02146716

Acronym

RESC

Enrollment

Registered

2014-05-26

Start date

2014-05-31

Completion date

2017-02-28

Last updated

2017-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Withdrawal Syndrome

Keywords

RESC, alcohol withdrawal syndrome

Brief summary

The purpose of RESC study is to assess the efficacy of Energetic Resonance by Cutaneous Stimulation on alcohol withdrawal symptoms measured by CUSHMAN score and in a second time to measure the benzodiazepine amount prescribed during the withdrawal time.

Interventions

OTHEREnergetic Resonance by Cutaneous Stimulation

Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Men and women between 18 and 80 years, * Patient with alcohol addiction, * Patient needing alcohol withdrawal in a hospital. * Patient with social Security, * Patient with inform consent signed.

Exclusion criteria

* Pregnant women * Minor. * Major with guardianship. * People without sufficient information because of troubles of cognitive functions, or without sufficient knowledge of French language.

Design outcomes

Primary

Measure	Time frame	Description
Cushman Score measure after Energetic Resonance by Cutaneous Stimulation	daily during one week	CUSHMAN score is represented by a scale with 7 variables collecting physiological modifications or behavioural manifestations related to adrenergic answer, neurovegetative signs, confusion, nervousness, perceptive or hallucinatory phenomena.

Secondary

Measure	Time frame
Anxiety depression scale	pre-screening, day 3 and day 7
prescribed benzodiazepine amount	day 0 to day 7
Analogic Visual Scale	before and after each Energetic Resonance by Cutaneous Stimulationsession at day 2, day 4 and day 6.
Quality of life scale	day 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026